Bone-Targeted Polymeric Nanoparticles for Implant Osseointegration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective strategies for local drug delivery at the surgical metal implant-bone tissue interface, particularly for therapeutic agents like growth factors that have short half-lives and require sustained presence for effective bone formation, and there is a need for flexible intraoperative modification of surgical implants to enhance osseointegration and tissue growth.
Innovation Solution
Development of bone and metal-targeted polymeric nanoparticles with a targeting element that selectively binds to bone and metal ions, a stealth layer to evade immune response, and a biodegradable core for sustained release of therapeutic agents, allowing for quick dip coating of surgical implants during procedures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If therapeutic agents are delivered systemically, then broad coverage is achieved, but non-specific application causes drastic side effects
Solution Approach 1:
The patent applies local quality by modifying only the surface of surgical implants with bone-targeting peptides and therapeutic agents, rather than systemic administration. This localized modification ensures that therapeutic effects are concentrated at the implant-bone interface where needed, while avoiding widespread exposure that causes side effects. The surface-modified implant delivers drugs locally to promote osseointegration without the drastic side effects of non-specific application.
2Manufacturing precision
If growth factors are applied locally at the implant site, then effective bone formation is promoted, but short half-life limits sustained presence
Solution Approach 1:
The patent applies preliminary action by pre-coating surgical implants with bone-targeting peptides and therapeutic agents before implantation. The surface modification is performed in advance during surgical procedures, allowing the implant to immediately begin delivering therapeutic agents at the implant site. This preliminary preparation ensures sustained presence of growth factors at the bone-implant interface throughout the critical healing period, overcoming the short half-life limitation.
Solution Approach 2:
The patent uses bone-targeting peptides as intermediaries that bind to hydroxyapatite on bone surfaces and also bind therapeutic agents. This intermediary mechanism allows growth factors to be delivered sustainably at the implant site - the peptides act as carriers that remain bound to bone surfaces while releasing therapeutic agents over time, effectively extending the duration of action beyond the natural half-life of the growth factors themselves.
3Reliability
If implant surfaces are topologically modified, then integration into tissue is improved, but coating procedures are time-consuming and offer little for practical applications
Solution Approach 1:
The patent merges multiple functions into a single surface modification step: the implant surface is coated with bone-targeting peptides that simultaneously provide topological modification for improved osseointegration and serve as carriers for therapeutic agents. This combined approach achieves both enhanced tissue integration and localized drug delivery in one procedure, eliminating the need for separate time-consuming coating steps and making the process practical for surgical applications.
Solution Approach 2:
The patent employs thin film surface modification of implant surfaces with peptide and therapeutic agent coatings. This thin film approach provides flexible, practical coating that can be applied during surgical procedures without complex equipment or lengthy processing times. The thin film structure maintains the implant's mechanical properties while providing the necessary biological functionality for enhanced osseointegration and localized therapy.
4Measurement precision
If nanoparticles have high ligand density for improved targeting, then bone targeting is enhanced, but immune response may increase
Solution Approach 1:
The patent applies local quality by concentrating bone-targeting peptide ligands specifically at the nanoparticle surface where they contact bone hydroxyapatite, rather than distributing them throughout the entire nanoparticle structure. This localized placement of high-density ligands at the targeting interface achieves enhanced bone targeting accuracy while minimizing the overall immunogenicity of the nanoparticle, as the core structure can be designed with biocompatible materials that do not trigger strong immune responses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles provide prolonged and controlled delivery of therapeutic agents, enhancing osseointegration, promoting bone growth, and reducing infection at the implant site, with improved affinity and longevity at the bone or metal surface.
Implementation Method 1
a targeting element that selectively binds to bone, minerals, and/or metal ions
Implementation Method 2
a biodegradable polymeric material forming an inner core, which can carry therapeutic, prophylactic, or diagnostic agents
Data Source
AI summary
Bone- and metal-targeted polymeric nanoparticles are provided. Exemplary nanoparticles have three main components: 1) a targeting element that can selectively bind to bone, minerals, or metal ions; 2) a layer of stealth to allow the polymer to evade immune response; and 3) a biodegradable polymeric material, forming an inner core which can carry therapeutics or other diagnostics. Preferred nanoparticles contain a blend of target-element polymer conjugate and polymer that optimizes the ligand density on the surface of the nanoparticle to provide improved targeting of the nanoparticle. The ratio of target-element polymer conjugate to polymer can also be optimized to improve the half-life of the nanoparticles in the blood of the subject. The nanoparticles also exhibit prolonged, sustained release of therapeutic agents loaded into the particles.